SOUTH KOREA · PHARMA · MARKET ANALYSIS

Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

South Korea's pharma story in 2027 sits in exports, not the home market. Medicine exports reached USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. Two biosimilar developers led the world with 5 of 18 US FDA approvals in 2025 [MDToday 2026], while Songdo's contract bioreactor base — 785k L at Samsung Biologics alone [SBL FY25] — fills with patent-cliff, GLP-1 and BIOSECURE-driven demand toward 2030.

Executive summary

South Korea's pharmaceutical market is valued at approximately $26 billion in 2025, supported by National Health Insurance (NHI) universal coverage. The domestic industry has historically been dominated by generic manufacturers, but a strategic national investment in biopharmaceuticals has produced genuine global capabilities: Samsung Biologics is the world's largest biopharmaceutical contract manufacturer by capacity, and Celltrion launched the world's first biosimilar infliximab. Korean biopharmaceutical companies are increasingly competitive in the global biosimilar market, generating significant export revenue to the US and Europe. Domestic R&D investment has grown to 6.2% of industry revenue, supporting new drug pipeline development particularly in oncology and autoimmune therapeutics. This report covers Korea's pharmaceutical market by segment, NHI reimbursement dynamics, biosimilar industry development, Samsung Biologics CDMO strategy, domestic generic landscape, and the export outlook through 2027.

Report details

Published
2026-06-02
Pages
15
Format
PDF
Code
KR-PHA-XPL-D27-01
Market
South Korea
Industry
Pharma
Year
2026

Table of contents · 12 sections

  1. 04 Executive summary
  2. 05 Strategic implications
  3. 06 Demand & the export engine
  4. 07 Market size & the export mix
  5. 08 Korea's global biosimilar position
  6. 09 CDMO capacity build
  7. 10 The Songdo capacity race
  8. 11 What fills the new capacity
  9. 12 Biosimilar global expansion
  10. 13 Six patent-cliff windows
  11. 14 Regulatory & policy ladder
  12. 15 2025-2030 forecast & sources

The full report is available to subscribers and buyers. The executive summary above is free to read.

Key questions

What does KIRA forecast for South Korea's medicine exports in 2027?

KIRA's forecast puts South Korean medicine exports at USD 12.8 bn in 2027, up from USD 10.4 bn in 2025, according to KIRA's 2026 market report (KIRA triangulation of KPBMA and Korea Customs data).

Source: Kira estimates, 2027 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

What revenue and new orders did Samsung Biologics report in 2025?

Samsung Biologics reached KRW 4.56 trn of revenue and KRW 6 trn of new orders in 2025, according to KIRA's 2026 market report (SBL FY25).

Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How many FDA biosimilar approvals did Korean companies win in 2025?

Korean companies won 5 of 18 US FDA biosimilar approvals in 2025, the most of any country, led by Celltrion and Samsung Bioepis, according to KIRA's 2026 market report (MDToday 2026).

Source: MDToday 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How large were South Korea's pharmaceutical exports in 2025?

South Korea's pharmaceutical exports reached USD 10.4 bn in 2025, up 11.8% year on year, with biologics at 62.6% of the total, according to KIRA's 2026 market report (KPBMA 2026).

Source: KPBMA 2026, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How much bioreactor capacity does Samsung Biologics have in Songdo?

Samsung Biologics' Songdo plants 1-5 hold 785k L of bioreactor capacity, according to KIRA's 2026 market report (SBL FY25).

Source: SBL FY25, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How big is South Korea's domestic pharma market?

Domestic pharma is a slow-growing base of about USD 23 bn in 2025, on a trajectory of about 2.4%, according to KIRA's 2026 market report (Korea Pharma Outlook 2025).

Source: Korea Pharma Outlook 2025, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

What does the third five-year bio plan target by 2030?

The third five-year bio plan targets doubled bio exports and three blockbuster drugs by 2030, according to KIRA's 2026 market report.

Source: KIRA research, 2030 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How does the BIOSECURE Act affect Korean contract manufacturers?

The BIOSECURE Act, signed into the FY26 NDAA, redirects US demand that Chinese CDMOs lose to Korean plants, according to KIRA's 2026 market report (Lawtimes 2026).

Source: Lawtimes 2026, 2026 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

How many active clinical trials are running in South Korea?

Active clinical trials in Korea fell to 2,175 in 2025 from 2,307, a warning sign for the pipeline, according to KIRA's 2026 market report.

Source: KIRA research, 2025 · KIRA report: Korea pharma 2027 — biosimilars go global, the CDMO capacity build compounds

More on Pharmaceuticals in South Korea